Cargando…

PB1724: NILOTINIB PLUS CHEMOTHERAPY IN PEDIATRICS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LEUKEMIA: A SINGLE CENTER EXPERIENCE

Detalles Bibliográficos
Autores principales:	LI, Yanming, Qi, Peijing, Wu, Ying, Lin, Wei, Zhang, Ruidong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429907/ http://dx.doi.org/10.1097/01.HS9.0000973756.31523.1a

Ejemplares similares

PB1740: THE COMBINATION OF PONATINIB PLUS CHEMOTHERAPY UPFRONT ACHIEVES DURABLE COMPLETE MOLECULAR REMISSIONS IN ADULTS PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA.
por: Sotirios, Papageorgiou, et al.
Publicado: (2023)

PB1757: VARIANT PHILADELPHIA CHROMOSOME IN ALL
por: Bouayed Abdelmoula, N., et al.
Publicado: (2022)

PB1891: VARIANT PHILADELPHIA CHROMOSOME IN CML
por: Bouayed Abdelmoula, N., et al.
Publicado: (2022)

PB1843: ACUTE MYELOID LEUKEMIA WITH PHILADELPHIA CHROMOSOME: EXPERIENCE OF SFAX HEMATOLOGY DEPARTMENT
por: Siala, N., et al.
Publicado: (2022)

PB1763: A PHASE 1/2 STUDY TO EVALUATE PONATINIB WITH CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH RELAPSED/RESISTANT/INTOLERANT PHILADELPHIA CHROMOSOME–POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA OR WITH T315I MUTATION
por: Gore, L., et al.
Publicado: (2022)

PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY
por: Jabbour, E., et al.
Publicado: (2022)

PB2054: HIP AND KNEE OSTEOARTHRITIS IN PHILADELPHIA CHROMOSOME-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Holik, H., et al.
Publicado: (2022)

PB1750: PHILADELPHIA CHROMOSOME POSITIVE ALL EGYPTIAN PATIENTS: CLINICAL PROFILE & OUTCOME. A SINGLE CENTER EXPERIENCE.
por: Shaaban, Yasmine, et al.
Publicado: (2023)

PB2058: IMPACT OF COMORBIDITIES AND RESPONSE TO TREATMENT ON THE MPN SAF ASSESSMENT OF PHILADELPHIA CHROMOSOME NEGATIVE MYELOPROLIFERATIVE SYNDROMES.
por: Mohamed, B., et al.
Publicado: (2022)

PB1968: IMPACTS ON OUTCOMES AND A PREDICTIVE MODEL OF SEVERE THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA RECEIVING INITIAL NILOTINIB-THERAPY
por: LI, Ziyu, et al.
Publicado: (2023)

PB1742: FEASIBILITY AND EFFICACY OF A PEG-ASPARAGINASE-BASED TREATMENT PROTOCOL IN ELDERLY PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS
por: Vernarecci, Chiara, et al.
Publicado: (2023)

PB1829: ARGENTINEAN REAL WORLD EXPERIENCE ON MIDOSTAURIN PLUS INTENSIVE CHEMOTHERAPY VS INTENSIVE CHEMOTHERAPY TO TREAT FLT3 POSITIVE ACUTE MYELOID LEUKEMIA PATIENTS
por: Navickas, A., et al.
Publicado: (2022)

PB1906: HYPOMETHYLATING AGENT PLUS LOW DOSE VENETOCLAX – A CHEMOTHERAPY-FREE INDUCTION OF ACUTE MYELOID LEUKEMIA TO ACHIEVE COMPLETE REMISSION IN PATIENTS UNFIT FOR CHEMOTHERAPY
por: Kumar, Karthik, et al.
Publicado: (2023)

PB1816: CHEMOTHERAPY FREE APPROACH IN A PEDIATRIC PATIENT WITH VERY LATE CUTANEOUS RELAPSE OF ACUTE PROMYELOCYTIC LEUKEMIA.
por: Crisci, V., et al.
Publicado: (2022)

PB1972: ASC4START: A PHASE IIIB, OPEN-LABEL, RANDOMIZED STUDY OF ASCIMINIB VERSUS NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED PH+ CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE
por: Hochhaus, Andreas, et al.
Publicado: (2023)

PB1801: CHROMOSOMAL ABNORMALITIES DURING THE CLINICAL COURSE OF ADULT ACUTE MYELOID LEUKEMIA
por: Zotova, O., et al.
Publicado: (2022)

PB2212: ABDOMINAL AORTIC CALCIFICATION IN PATIENTS NEWLY DIAGNOSED WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASM
por: Lee, Myung-Won, et al.
Publicado: (2023)

PB1861: EFFICACY AND TOXICITY OF VENETOCLAX PLUS HYPOMETHYLATING AGENTS IN THE REAL LIFE OF ACUTE MYELOID LEUKEMIA
por: Martini, Gianluca, et al.
Publicado: (2023)

PB1799: KMT2A-REARRANGED PEDIATRIC ACUTE MYELOID LEUKEMIA
por: Zerkalenkova, E., et al.
Publicado: (2022)

PB1745: SURVIVAL AND PROGNOSTIC FACTORS OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA IN OMAN.
por: Almamari, Moza, et al.
Publicado: (2023)

PB1776: ABC TRANSPORTERS AFFECT THE SENSITIVITY OF ACUTE MYELOID LEUKEMIA BLASTS TO CHEMOTHERAPY
por: Cerovska, E., et al.
Publicado: (2022)

PB2275: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB PLUS CHEMOTHERAPY VERSUS RITUXIMAB PLUS CHEMOTHERAPY IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-2)
por: Novelli, Silvana, et al.
Publicado: (2023)

PB1830: HIGH EARLY MORTALITY RATES IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY IN TWO ACADEMIC CENTERS IN BRAZIL
por: Lisboa Nogueira, F., et al.
Publicado: (2022)

PB1716: COMPARISON BETWEEN CONVENTIONAL KARYOTYPING AND INTERPHASE FISH ON AIR-DRIED SMEARS IN EVALUATING STRUCTURAL CHROMOSOMAL ABNORMALITIES AMONG PEDIATRIC ACUTE LEUKEMIA PATIENTS
por: Bommannan, Karthik, et al.
Publicado: (2023)

PB1751: ALTERATIONS IN THE GUT MICROBIOME IN PEDIATRIC, ADOLESCENT, AND YOUNG ADULT PATIENTS WITH ACUTE LEUKEMIA
por: Park, M., et al.
Publicado: (2022)

Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
por: Emole, Josephine, et al.
Publicado: (2016)

PB2022: ELTROMBOPAG IN MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA: A SINGLE-CENTER EXPERIENCE
por: Peña, Amaia Lopez, et al.
Publicado: (2023)

PB2356: EFFECTS OF TARGETED NURSING INTERVENTIONS ON CANCER-INDUCED FATIGUE AND MENTAL HEALTH IN CHEMOTHERAPY PATIENTS WITH LEUKEMIA
por: Xiao, S., et al.
Publicado: (2022)

PB1809: CLINICAL TRAJECTORY OF LONG-TERM SURVIVORS OF ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE INDUCTION CHEMOTHERAPY
por: Heering, G., et al.
Publicado: (2022)

PB1767: OUTCOME OF RELAPSED CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA IN THE SOUTH OF TUNISIA SINGLE CENTER EXPERIENCE
por: Siala, N., et al.
Publicado: (2022)

PB2238: ATYPICAL CHRONIC MYELOID LEUKEMIA. CLINICAL AND MOLECULAR FEATURES. A SINGLE CENTER EXPERIENCE.
por: Martínez, Javier Alberto Rojas, et al.
Publicado: (2023)

PB1812: CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA IN PEDIATRIC POPULATION: THE RESULTS OF A MONOCENTRIC EXPERIENCE
por: Charfi, H., et al.
Publicado: (2022)

PB1827: ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
por: Marques, I., et al.
Publicado: (2022)

PB1760: AZACITIDINE AS TREATMENT OF KMT2A INFANT ACUTE LYMPHOBLASTIC LEUKEMIA: SINGLE CENTER EXPERIENCE
por: Giagnuolo, G., et al.
Publicado: (2022)

PB1890: TRIAL IN PROGRESS: A PHASE II STUDY OF MIDOSTAURIN COMBINED WITH INDUCTION/CONSOLIDATION CHEMOTHERAPY AND AS SINGLE-AGENT MAINTENANCE IN PEDIATRIC PATENTS WITH FLT3-MUTATED ACUTE MYELOID LEUKEMIA
por: Reinhardt, Dirk, et al.
Publicado: (2023)

PB2257: OUTCOME AND PROGNOSTIC FACTORS OF PEDIATRIC PATIENTS WITH HODGKIN LYMPHOMA: A SINGLE-CENTER EXPERIENCE
por: Ali, Nesreen, et al.
Publicado: (2023)

PB1813: REGULATORY MECHANISMS AND THERAPEUTIC POTENTIAL OF THE DLK1-DIO3 LOCUS IN PEDIATRIC ACUTE MEGAKARYOBLASTIC LEUKEMIA
por: Verboon, Lonneke, et al.
Publicado: (2023)

Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL
por: Kong, Yuan, et al.
Publicado: (2017)

PB1807: OUTCOME OF CORE BINDING FACTOR ACUTE MYELOID LEUKEMIA IN CHILDREN AND ADOLESCENTS: A SINGLE CENTER EXPERIENCE
por: Ben Sayed, N., et al.
Publicado: (2022)

PB2006: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH PLASMA CELL LEUKEMIA (PCL): A SINGLE-CENTER STUDY FROM TUNISIA
por: Fakhfakh, Y., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ujmvidr9c2l04h9ovma6m78po3